I[C:2]1[C:3]([NH:16][CH:17]2[CH2:22][CH2:21][CH2:20][N:19]([C:23]([O:25][C:26]([CH3:29])([CH3:28])[CH3:27])=[O:24])[CH2:18]2)=[N:4][C:5]([N:10]2[CH2:15][CH2:14][O:13][CH2:12][CH2:11]2)=[N:6][C:7]=1[O:8][CH3:9].[N:30]1([C:35]2[S:36][CH:37]=[C:38](B3OC(C)(C)C(C)(C)O3)[N:39]=2)[CH:34]=[CH:33][CH:32]=[CH:31]1.C([O-])([O-])=O.[Cs+].[Cs+]>[Pd+2].Cl[Cu].CN(C=O)C>[N:30]1([C:35]2[S:36][CH:37]=[C:38]([C:2]3[C:3]([NH:16][C@@H:17]4[CH2:22][CH2:21][CH2:20][N:19]([C:23]([O:25][C:26]([CH3:28])([CH3:29])[CH3:27])=[O:24])[CH2:18]4)=[N:4][C:5]([N:10]4[CH2:11][CH2:12][O:13][CH2:14][CH2:15]4)=[N:6][C:7]=3[O:8][CH3:9])[N:39]=2)[CH:34]=[CH:33][CH:32]=[CH:31]1In a 40 mL vial chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2-aminoethyl)phenyl)]-palladium(II) (0.023 g, 0.029 mmol), tert-butyl 3-((5-iodo-6-methoxy-2-morpholinopyrimidin-4-yl)amino)piperidine-1-carboxylate (Compound (21) (0.15 g, 0.289 mmol), 2-(1H-pyrrol-1-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiazole (0.088 g, 0.318 mmol) and CuCl (0.031 g, 0.318 mmol) were combined. This mixture was then evacuated and backfilled with argon. Then DMF (2.89 ml) and Cs2CO3 (0.376 g, 1.16 mmol) were added to this flask all under argon. This mixture was then heated at 100° C. for 18 h. The mixture was cooled, filtered, diluted with ethyl acetate (mL), washed with water, then dried (Na2SO4), filtered and the solvent was evaporated under reduced pressure. The residue was purified via column chromatography. (0-50% EtOAc/hexane) to give the title compound as a white solid. MS (m/z)=542 (M+H).
불러오는 중…